ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
The drug is also intended for the treatment of glioblastoma multiforme
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Subscribe To Our Newsletter & Stay Updated
